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AbstrACt
Introduction While there is mounting evidence of 
the independent prognostic value of patient-reported 
outcomes (PROs) for overall survival (OS) in patients with 
cancer, it is known that the conduct of these studies 
may hold a number of methodological challenges. The 
aim of this systematic review is to evaluate the quality of 
published studies in this research area, in order to identify 
methodological and statistical issues deserving special 
attention and to also possibly provide evidence-based 
recommendations.
Methods and analysis An electronic search strategy will 
be performed in PubMed to identify studies developing 
or validating a prognostic model which includes PROs as 
predictors. Two reviewers will independently be involved 
in data collection using a predefined and standardised 
data extraction form including information related to study 
characteristics, PROs measures used and multivariable 
prognostic models. Studies selection will be reported 
following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines, with data 
extraction form using fields from the Critical Appraisal 
and Data Extraction for Systematic Reviews of Prediction 
Modelling Studies (CHARMS) checklist for multivariable 
models. Methodological quality assessment will also be 
performed and will be based on prespecified domains 
of the CHARMS checklist. As a substantial heterogeneity 
of included studies is expected, a narrative evidence 
synthesis will also be provided.
Ethics and dissemination Given that this systematic 
review will use only published data, ethical permissions 
will not be required. Findings from this review will 
be published in peer-reviewed scientific journals and 
presented at major international conferences. We 
anticipate that this review will contribute to identify 
key areas of improvement for conducting and reporting 
prognostic factor analyses with PROs in oncology and will 
lay the groundwork for developing future evidence-based 
recommendations in this area of research.
Prospero registration number CRD42018099160.
IntroduCtIon  
Patient-reported outcomes (PROs) play a key 
role in cancer research in addition to traditional 
clinical outcomes, such as overall survival (OS) 
or tumour response.1 2 
A PRO is an umbrella term covering a 
measurement of any aspect of a patient’s health 
status directly reported from the patient, and 
it is now included by the US, Food and Drug 
Administration (FDA) among the four types 
of Clinical Outcomes Assessment (COA) 
measures that can be used to determine 
whether drugs provide a treatment benefit.3 
The value of including PROs as endpoints in 
comparative studies is that of generating data 
strengths and limitations of this study
 ► This systematic review will critically evaluate the 
methodological quality of recent studies in oncology 
in order to examine the robustness of patient-re-
ported outcomes (PROs) as independent prognostic 
factors for overall survival (OS). Compared with the 
existing literature, it will extensively consider and 
evaluate recently published studies in all cancer 
sites and all types and measures of PROs.
 ► The main strength of our review is the amount of rel-
evant information, related to both clinical outcomes 
and methodological issues, collected through the 
designed data-extraction form.
 ► Another key strength of our review is that it will 
contribute to identify key areas of potential improve-
ment for conducting methodologically sound prog-
nostic modelling analyses, and would contribute 
to healthcare delivery; for example, by improving 
management of patients in clinical practice and by 
informing a more accurate stratification of patients 
in clinical trials.
 ► The main limitation of this systematic review might 
be the heterogeneity of selected studies in terms of 
study design and study population, therefore limiting 
our ability to provide strong recommendations for a 
specific cancer population.
 ► An additional limitation of this study is that we will 
only search one database.
 o
n
 7 N
ovem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025054 on 24 October 2018. Downloaded from 
2 Deliu N, et al. BMJ Open 2018;8:e025054. doi:10.1136/bmjopen-2018-025054
Open access 
that can be used to more robustly inform patient care. 
The increased use of PROs in clinical trials4 also reflects a 
growing recognition by major international health policy 
and regulatory authorities, of the importance of PROs in 
providing additional information about benefits, risks and 
cost of therapy, thus supporting claims in approved medical 
product labelling.5–7
While PROs are frequently included in clinical trial 
settings for treatment outcome comparisons, a more recent 
line of research has indicated that PROs, including func-
tional aspects and symptomatic dimensions, can also provide 
additional prognostic information for survival outcomes. 
Furthermore, in some specific cancer populations, it has 
been shown that prognostic accuracy of well-established and 
validated prognostic models, based on laboratory and clin-
ical data, can be improved by adding PROs.8
One of the most comprehensive critical reviews of studies 
investigating the prognostic value of baseline PROs on 
patients’ survival was reported by Gotay et al.9 Notably, out 
of the 39 clinical trials reviewed and published from 1989 
to 2006, 36 studies found at least one PRO associated with 
OS in the multivariable analysis. PROs most frequently asso-
ciated with OS are global quality of life (QoL) and physical 
functioning (PF). Further evidence that PROs provide addi-
tional prognostic value beyond traditional clinical measures 
in patients with cancer has been reported in several 
secondary pooled analyses of EORTC clinical trials.10–13 For 
example, a large meta-analysis published in 2009 by Quinten 
et al,11 comprising 30 randomised controlled trials (RCTs), 
including data for >7000 patients with a variety of cancers, 
found that including both traditional predictors and PROs 
in multivariable analyses increased the ability to predict 
OS by 6% compared with traditional information alone. 
These findings have been replicated across other cancer 
populations, further strengthening the scientific grounds 
of this association.14–23 It is worth highlighting that diverse 
PRO questionnaires are often used which has frequently 
hindered clear comparisons across studies.9
rAtIonAlE
The completeness of reporting of studies describing 
the development or validation of prediction models in 
medicine, in general, is known to be suboptimal and 
major efforts have been made in recent years to raise 
standards and transparency of such studies. The Trans-
parent Reporting of a multivariable prediction model for 
Individual Prognosis or Diagnosis (TRIPOD) Statement 
has been recently developed to guide authors of reports 
describing prediction models.24
While there is a substantial body of literature docu-
menting the association between PROs and survival 
outcomes, there is also an indication that the design, model-
ling techniques and reporting of many of these studies are 
frequently plagued by a number of methodological short-
comings.25 The inclusion of PROs into studies of prognosis 
holds several major challenges. As PROs questionnaires are 
actually developed to measure the patient’s perspective of 
disease or treatment burden, they typically include multi-
domains which often measure aspects of a patient’s health 
status that might be, more or less, correlated with each 
other. Indeed, one of the key methodological challenges 
is the possible harmful multicollinearity among questionnaire 
subscales entering the analysis, which may negatively affect 
the  stability of the final prognostic model.26
One of the most rigorous reviews examining the method-
ological quality of studies evaluating the prognostic value 
of PROs was published by Mauer et al.25 In this systematic 
review (which included studies published between 1989 
and 2006), the authors found that most analyses were 
undertaken retrospectively, and on an exploratory basis, 
often not preplanned in the original study protocol. Also, 
the selection process for the prognostic factors was rarely 
described, and only in one study,27 for example, the total 
number of included predictors relative to the total number 
of deaths, as recommended by Harrell et al,28 was checked. 
Correlations among all PRO domains included in the 
model were rarely investigated, therefore limiting a critical 
appraisal of the potential impact of multicollinearity in final 
model selection.26 29 Finally, most studies lacked an assess-
ment of the added prognostic value of individual PROs as 
compared with traditional clinical factors alone, and none 
of the publications reviewed by Mauer et al25 reported an 
external validation of the multivariable model (ie, an evalu-
ation of model performance on a new dataset of patients).
While the independent prognostic value of PROs has 
been documented across many cancer disease sites and 
in several studies, the lack of methodological and analytic 
rigour makes current evidence far from being conclusive, 
likely undermining the translation of findings into real-
world practice applications.25 Therefore, a critical evalua-
tion of the methodological quality of most recent studies 
is needed in order to examine the robustness of PROs 
included in prognostic models for OS.
objECtIvEs
The aim of this systematic review is to critically investigate 
and report the quality of studies assessing the prognostic 
value of PROs for OS to identify methodological areas 
in need of particular attention and to provide evidence-
based recommendations.
The specific aims of this systematic review are:
 ► To investigate the methodological quality of cancer 
prognostic modelling studies incorporating PRO data.
 ► To examine whether the methodological quality of 
these studies has improved over time.
 ► To describe the prognostic significance of PROs across 
different cancer types, stages and treatments.
MEthods And AnAlysIs
This systematic review protocol adheres to the preferred 
reporting process and checklist outlined within the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses for Protocols 2015 (PRISMA-P) guide-
lines30 (online supplementary file 1). In accordance with 
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these guidelines, this systematic review protocol has been 
registered with the International Prospective Register of 
Systematic Reviews (PROSPERO) on 28 June 2018 under 
registration number CRD42018099160. At the time of 
PROSPERO submission, formal screening of search 
results against eligibility criteria was ongoing. Any amend-
ments to the study protocol will be documented contem-
poraneously on the PROSPERO database site.
ElIgIbIlIty CrItErIA
types of studies
According to the checklist for critical appraisal and data 
extraction for systematic reviews of prediction modelling 
studies (CHARMS) checklist31 the proposed review will 
include:
 ► Prognostic model development studies without 
external validation on independent data.
 ► Prognostic model development studies with external 
validation on independent data.
 ► External model validation studies.
As a comprehensive review on the prognostic role of 
PROs for survival has already been published outcomes 
in 2008,25 this systematic review will be based on the 
most recent literature, that is, previous 5 years (January 
2013 to December 2017). All studies’ designs, thus also 
secondary data analyses, will be considered for inclu-
sion. This specific time window for the identification of 
studies published within the previous 5 years was selected 
in order to provide state of the art evidence in this area 
and to also possibly compare our recent findings with 
previously published work, reporting on older studies.25 
Only English language articles will be considered. Grey 
literature such as reports or working papers, conference 
presentations, opinions or commentaries and literature 
reviews will be excluded.
Participants
We will include studies on patients with a confirmed diag-
nosis of any cancer type, whatever stage and treatment(s) 
received. Both male and female adult patients (aged ≥18 
years) will be considered.
types of prognostic models
We will assess multivariable prognostic models and valida-
tion studies developed for patients with cancer with the 
following characteristics:
 ► OS as the outcome to be predicted, where OS is 
defined as the time from a prespecified time point 
(eg, date of randomisation, date of diagnosis and 
date of start of treatment) until death from any cause. 
Models predicting survival outcomes other than OS, 
for example, disease-free survival, progression-free 
survival or survival rate, will not be considered for 
inclusion.
 ► At least one baseline PRO as a predictor, defined as 
a patient-reported indicator of well-being and meas-
ured with a multidimensional instrument. A baseline 
PRO might be a PRO collected at any fixed prede-
fined time point, for example, before the start of 
intervention, before randomisation or, in general, at 
study entry. Studies reporting only changes in PRO 
scores will be excluded, as such measures may reflect 
rather than predict changes in survival time related to 
disease status.
Studies examining the association of baseline PROs with 
OS in a univariate or unadjusted fashion analysis only, 
without controlling for sociodemographic or clinical param-
eters, will not be included in this systematic review.
search strategy
An electronic search strategy will be performed in PubMed 
to identify studies that match our eligibility criteria. As 
specific search filters are not available neither for PROs 
nor for prognostic studies, available published filters will 
be adapted and combined for a highly sensitive search 
strategy.32 We will use medical subject heading (MeSH) 
and free-text words related to PROs and broad statistical 
strategies to identify prognostic modelling studies incor-
porating at least one PRO parameter and limited to adult 
(≥18 years old) cancer populations. Details on the key 
searching strategy used are reported in the online supple-
mentary file 2 (PubMed key search).
Recognising potential limitations of electronic search 
strategies, we will supplement our search to identify 
potentially relevant studies from other sources, including 
reference lists of included studies, index-related articles 
on PubMed and existing relevant reviews.
study selection and data extraction
Articles identified through database searching will be 
exported from PubMed into Microsoft Excel and dupli-
cate records will be removed electronically. Record 
screening will occur in the exported Excel file to ensure 
that all retrieved references are fully tracked. One 
reviewer will compare the titles and abstracts yielded by 
the search against the inclusion criteria and will select 
articles for a full-text review. A second reviewer will 
confirm articles identified as eligible for inclusion, and 
reasons for exclusion will be documented for all excluded 
articles. The selection process, including search results 
and the reason for exclusion, will be reported in a flow 
diagram, as recommended in the PRISMA statement.33
At least two trained reviewers will independently be 
involved in the data extraction of studies meeting the 
eligibility criteria, which will be uploaded in a Google 
Drive folder for complete review. Data collection will 
be performed electronically in the non-proprietary 
Research Electronic Data Capture (REDCap, Vanderbilt 
University, USA; https://www. project- redcap. org/) plat-
form,34 which is a secure web application developed for 
building and managing online surveys and databases. 
Each reviewer will be provided with a personal password 
to access the study website and complete a standardised 
electronic data extraction form (eDEF).
 o
n
 7 N
ovem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025054 on 24 October 2018. Downloaded from 
4 Deliu N, et al. BMJ Open 2018;8:e025054. doi:10.1136/bmjopen-2018-025054
Open access 
The eDEF will collect information related to study 
characteristics (eg, study design/source of data, study 
objectives and study population) and PROs (eg, type of 
questionnaire used, handling of PROs in multivariate 
analysis, compliance and their association with OS). It 
will also include fields relevant to multivariable models, 
based on CHARMS31 and TRIPOD24 checklists, including 
modelling method, handling of predictors, predictors 
selection process, model performance and evaluation.
Items included in the eDEF were piloted in a sample of 
similar previously published (ie, prior January 2013) articles 
to assess their clarity and applicability. The full list of items 
included in the eDEF (see box 1) along with a compre-
hensive guideline on how to evaluate them is available to 
reviewers. This guideline is meant to minimise the number 
of discrepancies arising from the reviewing process. Should 
disagreements arise regarding extracted data, the reviewers 
will discuss and revisit the paper to reconcile any differences 
until consensus will be achieved. The reconciliation process 
will be facilitated by consulting a third senior reviewer or 
contacting study authors, if necessary. The final eDEF will 
then be validated by the project manager and locked for 
a final analysis.
We confirm that we have already started articles screening 
(January 2018) and we are currently validating the studies 
resulted eligible for inclusion. We plan to complete data 
extraction by the end of 2018.
Methodological quality assessment
Critical appraisal of methodological quality and risk of 
bias of included papers will be undertaken independently 
by two or more reviewers according to an adapted version 
of the CHARMS checklist for critical appraisal of prog-
nostic model studies.31 Following these guidelines, the 
reviewers will extract from individual studies relevant 
items belonging to the following domains: source of data, 
participants, outcome to be predicted, candidate predic-
tors, sample size, missing data, model development, 
model evaluation and results (see box 1).
For each criterion, judgement will be made using one 
of the following three categories:
1. Low risk: if the criterion is adequately fulfilled in the 
study, that is, the study is at a low risk of bias for the 
given criterion.
2. High risk: if the criterion is not fulfilled in the study, 
that is, the study is at high risk of bias for the given 
criterion.
3. Unclear: if the study report does not provide sufficient 
information to allow for a clear judgement or if the 
risk of bias is unknown for one of the criteria listed 
above.
Presenting and reporting results
The selection process, including search results and 
the reason for exclusion, will be reported in a flow diagram, 
as recommended by the PRISMA statement.33
Data obtained from each eligible study will be summarised 
by providing descriptive tables reporting authors’ names, 
box 1 domains and items of the EPIPhAny data 
extraction form
1. Analysis type
 – Type of study analysis.
2. Study characteristics (model development)
 – First author.
 – Journal title.
 – Year of publication.
 – Cancer type.
 – Cancer stage.
 – Broad treatment type.
 – Was this study a secondary data analysis?
 – Source of data/study design.
 – Was the prognostic model incorporating PRO the primary objec-
tive of the study?
 – If no, what was the primary objective?
 – If yes, was sample size determination based on the primary ob-
jective (ie, prognostic model development/validation)?
 – Primary outcome predicted by the prognostic model.
 – Secondary outcomes predicted by the prognostic model.
 – Was the prognostic model with PRO identified in the abstract?
 – Any rationale for including PRO in the prognostic model?
 – Please specify when were baseline PROs collected.
 – Type of PRO instruments used.
3. Multivariable model and predictors (model development)
 – Multivariable model used.
 – Were model assumptions assessed and reported.
 – Was the number of events (deaths) checked in relation to the 
number of candidate predictors (Events per Variable)?
 – The rationale for the choice of PRO candidate variables used to 
build the final model.
 – Strategy to build the final model.
 – If stepwise, forward or backward, which stopping criterion was 
used?
 – Was multicollinearity among baseline PRO variables investigated?
 – If yes, which technique was used to account for baseline PRO 
multicollinearity?
 – Were any interactions among predictors examined?
 – How were continuous baseline PRO predictors handled?
 – If any continuous baseline PRO predictor, did the authors report 
its range?
 – For continuous baseline PRO that was categorised/dichotomised, 
how was this done?
 – Have the authors been clear on the number of categories of 
baseline PRO predictors?
 – Did the authors evaluate the performances of the prognostic 
model?
 – Which kind of measures were used to evaluate model performance?
 – Any additional analyses carried out?
4. Missing data (model development)
 – Were missing covariates mentioned in the paper?
 – The extent of missing baseline PRO questionnaires was reported.
 – If yes:
 – Report the number of returned PRO questionnaires.
 – Report the number of due PRO questionnaires.
 – The extent of missing baseline PRO data was given for each scale 
separately.
 – Is there any evidence of comparison of baseline sociodemo-
graphic and clinical characteristics of patients with and without 
completed baseline PRO questionnaires?
Continued
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publication year, study sample, type of cancer, instrument 
used to measure PRO and the main methodological find-
ings (eg, multivariable model used, selection procedure, 
type of model validation, missing data information and 
model performance).
All relevant issues related to the methodological quality 
will be carefully reported and described separately. 
Results from the risk of bias assessment will be presented 
as counts and percentages, highlighting the most critical 
domains affecting the overall risk of bias.
Patient and public involvement
No patients will be involved in this study.
Ethics and dissemination
Given that this systematic review will use only published 
data, ethical permissions will not be required. Findings 
from this review will be published in peer-reviewed scien-
tific journals and presented at international conferences 
relevant to various research fields of cancer outcomes 
research, biostatistics and QoL.
ConClusIon
The risk of bias and potential usefulness of prediction 
models can be adequately assessed only by clear and 
full reporting of information, about all steps regarding 
their development and validation. Well-conducted and 
reported prognostic model studies with a PRO predictor 
box 1 Continued
 – If the authors updated the model, briefly describe what did they 
do.
7. Model validation (In case of external validation only)
 – Were any of the authors of the validation study an author of the 
development study?
 – Is the outcome (ie, OS) of the validation study different from that 
of the development study?
 – Please report OS of the population of the validation study.
 – Did the authors discuss the distribution of baseline patients’ 
characteristics of the validation study in comparison to those of 
the development study (either discussed or in tabulation)?
 – If yes, did they report that they are:
 – Were missing baseline PRO data mentioned in the validation 
study?
 – Were baseline PRO predictors coded the same as in the devel-
opment study?
 – If no, please report what were the discrepancies and the reasons.
 – If the prognostic model contained continuous baseline PRO risk 
predictors, were the ranges valid?
 – Did the authors validate the developed prognostic model or a 
simplified version of it?
8. Discussion/Conclusions
 – Did the authors discuss the PRO findings and their prognostic 
value on OS?
 – Did the authors compare the model to another existing model?
9. Comments
OS, overall survival; PRO, patient-reported outcome.
box 1 Continued
 – Is there any evidence of comparison of survival between patients 
with and without completed baseline PRO questionnaires?
5. Results (model development)
 – Overall number of patients analysed.
 – Age of patients.
 – Follow-up time.
 – Number of events (ie, deaths).
 – The overall number of candidate covariates considered prior to 
any model building and/or univariate screening.
 – Number of baseline PRO candidate covariates considered prior to 
any model building and/or univariate screening.
 – If (multi)collinearity was investigated:
 – Was (multi)collinearity among baseline PRO variables 
detected?
 – If yes, please specify (multi)collinear PRO covariates.
 – If yes, was any PRO excluded from model building process for 
(multi)collinearity reasons?
 – Total number of candidate variables entering in the multivariable 
model.
 – Total number of baseline PRO candidate variables entering the 
multivariable model.
 – Were any known risk factors forced into the model prior to build-
ing the final model?
 – Was the prognostic model adjusted for sociodemographic or clin-
ical characteristics?
 – The overall number of predictors included in the final model.
 – Did the final model include any baseline PRO predictor?
 – If Yes, please report the number of baseline PRO predictors in-
cluded in the final model.
 – Instruments of baseline PRO included in the FINAL model.
 – For each PRO included in the final model, please report the cor-
responding regression coefficient/HR.
 – For each PRO included in the final model, please report the cor-
responding SD/CI.
 – Please specify the confidence level of the reported CI.
 – Did the authors reported HRs for the number of points increase 
different from one unit (eg, for every ten-points increase)?
 – Were p values reported for all baseline PRO candidates entering 
in the multivariable model?
 – Standard errors or CIs reported for all coefficients or HRs of base-
line PRO candidates entering in the multivariable model?
 – Was a prognostic index developed?
 – Please report the value obtained for model performance.
 – Comparison of model performance with and without baseline 
PROs was done.
 – If yes, did baseline PROs increase predictive accuracy?
6. Model validation
 – Did the authors also validate the model?
 – If yes, how was this done?
 – Did the authors evaluate the performances of the validation prog-
nostic model?
 – If yes, Which kind of measures were used to evaluate validation 
model performance?
 – Did the authors discuss or mention concerns of overfitting/
optimism?
 – Have any modifications been suggested to the model based on 
the validation process?
 – Based on the validation findings, did the authors refit or recali-
brated the model?
Continued
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have great potential to improve healthcare delivery, for 
example, by improving the management of patients 
in clinical practice and by informing a more accurate 
stratification of patients in clinical trials. Our results will 
contribute to identifying key areas of improvement for 
conducting these analyses and will lay the groundwork for 
the development of evidence-based guidelines to improve 
the quality of research in this field.
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